GlobeNewswire

SEED Therapeutics Announces Poster Presentation at AACR Annual Meeting 2026
30/03/2026
KING OF PRUSSIA, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”) , a clinical-stage biotechnology company specializing in molecular glue degraders, today announced that it will have a poster [...]
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
30/03/2026
Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer PHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. ( [...]
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
30/03/2026
FLORHAM PARK, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and [...]
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
30/03/2026
- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically meaningful [...]
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
30/03/2026
Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the [...]
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
30/03/2026
Alignment reached on key elements of ATH434 Phase 3 development program MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the [...]
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
30/03/2026
Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company [...]
Appili Therapeutics to Exhibit at World Vaccine Congress Washington
30/03/2026
Appili Presentation Highlights Recent Collaborations and Funding Milestones Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities HALIFAX, Nova Scotia, March 30, [...]
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent
30/03/2026
Court preserves jury’s finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028 MENLO PARK, Calif., March 30, 2026 (GLOBE [...]
Kraig Biocraft Laboratories Deploys Over 700,000 BAM-1 Alpha Production Hybrids, Achieving Key Milestone in its Aggressive Scale-Up Plan
30/03/2026
ANN ARBOR, Mich., March 30, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced the successful [...]
Connect Biopharma Announces $20.2 Million Private Placement Financing
30/03/2026
Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma [...]
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
30/03/2026
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near ‑ maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to [...]
Micron Biomedical Named to Fast Company’s 2026 List of World’s Most Innovative Companies for Addressing the Most Significant Bottlenecks in How Medicine is Made, Distributed and Administered
30/03/2026
Recognition as second most innovative smaller company across all industries highlights transformative impact on public health, impactful industry collaborations, and a novel manufacturing approach that simplifies access [...]
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
30/03/2026
Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability [...]
Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network
30/03/2026
Hope Therapeutics (subsidiary of NRx Pharmaceuticals, Nasdaq: NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network. Emobot's platform [...]
Vireo Growth Inc. Announces Update on Non-Binding Memorandum of Understanding to Acquire The Hawthorne Gardening Company from ScottsMiracle-Gro
30/03/2026
Planned share-based transaction is expected to be completed during the second quarter of 2026 Vireo plans to appoint ScottsMiracle-Gro EVP Chris Hagedorn to its Board of Directors MINNEAPOLIS, March 30, 2026 (GLOBE [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
30/03/2026
COPENHAGEN, Denmark, March 30, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up [...]
Levicept Announces The Lancet Publication of LEVI-04 Phase II Clinical Trial Results, Showing Significant Reduction in Pain and Symptoms of Osteoarthritis
30/03/2026
Significant improvements in pain, function and patient global outcomes demonstrated LEVI-04 well tolerated and exhibits a favourable safety profile SANDWICH, United Kingdom, March 30, 2026 (GLOBE NEWSWIRE) -- Levicept [...]
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
30/03/2026
Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late- [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum